If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
== Fabrication == Graphene aerogels are synthetic materials that exhibit high porosity and low density. Typical syntheses of graphene aerogels involve reducing a precursor graphene oxide solution to form graphene hydrogel. The solvent can be subsequently removed from the pores by freeze-drying and replacing with air. The resulting structure consists of a network of covalently bonded graphene sheets surrounding large pockets of air, resulting in densities on the order of 3 mg cm−3. Graphene aerogel morphologies have also been demonstrated to be controllable through 3D printing methods. Graphene oxide ink composed of graphene oxide gelled in a viscous solution with the addition of silica to lower viscosity and enable printability of the graphene oxide ink. The ink is then extruded from a nozzle into isooctane, which prevents the ink from drying too quickly. Subsequently, the solvent can be removed by freeze drying, while the silica can be removed with a hydrofluoric acid solution. The resulting 3D lattice can be highly ordered while maintaining the high surface areas and low densities characteristic of graphene aerogels.
"Immigrant Women in the United States: A Demographic Portrait" Jill Esbenshade (Summer 2007). "Division and Dislocation: Regulating Immigration through Local Housing Ordinances". American Immigration Council Jeffrey S. Passel & Roberto Suro (September 2005). "Rise, Peak and Decline: Trends in U.S. Immigration" Archived 31 December 2007 at the Wayback Machine. Pew Hispanic Center Jeffrey S. Passel (March 2005). "Estimates of the Size and Characteristics of the Undocumented Population" Archived 31 December 2007 at the Wayback Machine. Pew Hispanic Center Jeffrey S. Passel (March 2007). "Growing Share of Immigrants Choosing Naturalization" Archived 28 December 2007 at the Wayback Machine. Pew Hispanic Center This article incorporates public domain material from Report for Congress: Agriculture: A Glossary of Terms, Programs, and Laws, 2005 Edition (PDF). Congressional Research Service. UNCTAD's Classification of Non-Tariff Measures (2012) report
=== Transition talks === In June 2026, representatives of the government and opposition held U.S.-backed talks in Caracas. The meeting, involving National Assembly president Jorge Rodríguez and former opposition lawmaker Dinorah Figuera, who was previously in exile, was described by participants as an effort to establish a platform for strengthening democracy and political stability. The United States welcomed the talks and stated that discussions included rebuilding democratic institutions, strengthening the National Electoral Council (CNE), restoring guarantees for political participation, and expanding civic freedoms. On 14 July 2026, the opposition-led National Assembly elected in 2015 and the incumbent National Assembly controlled by the government separately announced that a joint working agenda would begin on 1 August 2026. The statement issued by the 2015 National Assembly described the initiative as a roadmap to promote democratic institutions, electoral reforms, political participation, and national reconstruction following the June 2026 earthquakes. It also expressed appreciation for United States humanitarian assistance and support for democratic institutions. U.S. Secretary of State Marco Rubio shared the opposition communiqué on social media shortly after its publication, signaling support for the initiative.
Sources: en.wikipedia.org
The Librarians: The Next Chapter is an American fantasy adventure television series that is a direct spin-off of the Librarian film series, sharing continuity with the films and with The Librarians television series. The series stars Callum McGowan, Jessica Green, Olivia Morris, Bluey Robinson, and Caroline Loncq. The Librarians: The Next Chapter premiered on TNT on May 25, 2025 with its first season of twelve episodes. The second season premiered on August 2, 2026.
=== Former hospitals === Former UPMC hospitals include UPMC Sunbury in Sunbury, Pennsylvania (2017–2020) which was closed and services integrated into other nearby facilities; UPMC Beacon Hospital in Dublin, Ireland (2009 to 2014) which was acquired by Irish businessman Denis O'Brien; UPMC Braddock in Braddock, Pennsylvania (1996 to 2010) which was closed; UPMC South Side hospital in Pittsburgh (1996 to 2009) which was merged with UPMC Mercy and converted into UPMC Mercy South Side Outpatient Center; UPMC Lee Regional in Johnstown, Pennsylvania (1998 to 2005) which was sold to Conemaugh Health System; and UPMC Beaver Valley in Aliquippa, Pennsylvania (1996 to 2001) which was transferred back to its community board and subsequently closed. UPMC Pinnacle Lancaster, formerly St. Joseph's hospital in Lancaster, Pennsylvania, closed on February 28, 2019, and its services were consolidated into UPMC Pinnacle Lititz.
==== Elsewhere ==== Phenazepam was classified as a narcotic in Finland in July 2014. Phenazepam is considered a narcotic in Norway, as per a March 23, 2010 Health Department addition to the Regular Narcotic List. In Russia, phenazepam is a controlled substance since March 22, 2021. In Estonia, phenazepam is a Schedule IV substance under the Narcotic Drugs and Psychotropic Substances Act. Schedule IV is the lowest classification of psychoactive substances in Estonia. It includes prescribable drugs, including other benzodiazepines.
Sources: en.wikipedia.org
=== Generation and accumulation === Biomedical waste should be collected in containers that are leak-proof and sufficiently strong to prevent breakage during handling. Containers of biomedical waste are marked with a biohazard symbol. The container, marking, and labels are often red. Discarded sharps are usually collected in specialized boxes, often called needle boxes. Specialized equipment is required to meet OSHA 29 CFR 1910.1450 and EPA 40 CFR 264.173. standards of safety. Minimal recommended equipment include a fume hood and primary and secondary waste containers to capture potential overflow. Even beneath the fume hood, containers containing chemical contaminants should remain closed when not in use. An open funnel placed in the mouth of a waste container has been shown to allow significant evaporation of chemicals into the surrounding atmosphere, which is then inhaled by laboratory personnel, and contributes a primary component to the threat of completing the fire triangle. To protect the health and safety of laboratory staff as well as neighboring civilians and the environment, proper waste management equipment, such as the Burkle funnel in Europe and the ECO Funnel in the U.S., should be utilized in any department which deals with chemical waste. It is to be dumped after treatment. Operating Rooms ORs generate around one-third of waste in a hospital. This waste includes but is not limited to biohazards, plastic materials, pharmaceuticals, and linens. Moreover, ORs require large amounts of energy, causing a further negative environmental impact.
Noroxycodone is the major metabolite of the opioid analgesic oxycodone. It is formed from oxycodone in the liver via N-demethylation predominantly by CYP3A4. Noroxycodone binds to and activates the μ-opioid receptor (MOR) similarly to oxycodone, although with one-third of the affinity of oxycodone and 5- to 10-fold lower activational potency. However, although a potent MOR agonist, noroxycodone poorly crosses the blood-brain-barrier into the central nervous system, and for this reason, is only minimally analgesic in comparison.
In 1820, Michael Faraday liquefied ammonia and other gases by using high pressures and low temperatures, and in 1834, Jacob Perkins built the first working vapor-compression refrigeration system in the world. It was a closed-cycle that could operate continuously, as he described in his patent, "I am enabled to use volatile fluids for the purpose of producing the cooling or freezing of fluids, and yet at the same time constantly condensing such volatile fluids, and bringing them again into operation without waste." His prototype system worked although it did not succeed commercially. In 1842, a similar attempt was made by physician John Gorrie, who built a working prototype, but it was a commercial failure. Like many of the medical experts during this time, Gorrie thought too much exposure to tropical heat led to mental and physical degeneration, as well as the spread of diseases such as malaria. He conceived the idea of using his refrigeration system to cool the air for comfort in homes and hospitals to prevent disease. American engineer Alexander Twining took out a British patent in 1850 for a vapour compression system that used ether. The first practical vapour-compression refrigeration system was built by the journalist James Harrison. His 1856 patent was for a vapour-compression system using ether, alcohol, or ammonia. He built a mechanical ice-making machine in 1851 on the banks of the Barwon River at Rocky Point in Geelong, Victoria, and his first commercial ice-making machine followed in 1854.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.